rich 1.0 Arrowhead's plozasiran cut triglycerides up to 81% and pancreatitis events up to 100% in phase 3 trials, Greenwich LifeSciences expanded its GP2 breast cancer vaccine trial into the UK, and Ipsen completed its acquisition of Memo Therapeutics to add the first-in-class antibody potravitug to its rare disease pipeline. The BioPharm Brief https://audioboom.com/channels/5167274-the-biopharm-brief Audioboom https://audioboom.com 480 95 https://audioboom.com/i/43755737/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8931323/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>